source
- Former Legend Biotech CEO Ying Huang appointed head of K2 Therapeutics as startup secures $50M seed fundingYing Huang, who led Legend Biotech for seven years and helped develop a top‑selling cell therapy for multiple myeloma, has been named chief executive of K2 Therapeutics. The young company, founded…
- Trump pushes controversial changes to MMR vaccine policy, eclipsing new food additive rulePresident Trump has shifted the national conversation back to vaccine policy, calling for the measles‑mumps‑rubella (MMR) vaccine to be broken up into separate shots. The proposal has sparked immed…